A nurse is caring for a client who has several risk factors for hearing loss. Which of the following medications and/or classification of medication should alert the nurse to a further risk for ototoxicity? (Select All that Apply.)

Choice A rationale Amiodarone is a class III antiarrhythmic medication primarily utilized for ventricular and supraventricular tachycardias. Its common side effect profile includes pulmonary toxicity, thyroid dysfunction, and corneal microdeposits. Unlike certain other cardiac medications, it is not traditionally classified as a primary ototoxic agent. It does not typically cause significant damage to the hair cells of the cochlea or the vestibulocochlear nerve during standard therapeutic use. Choice B rationale Loop diuretics, such as furosemide, are well-documented ototoxic agents. These medications inhibit the sodium-potassium-chloride symporter in the thick ascending limb of the loop of Henle and can also alter the electrolyte balance in the stria vascularis of the inner ear. This disruption in endolymph composition can lead to temporary or permanent hearing loss and tinnitus, particularly when administered rapidly or at high doses via intravenous routes. Choice C rationale Nonsteroidal anti-inflammatory drugs, or NSAIDs, including aspirin and ibuprofen, can cause ototoxicity when taken in high doses. These agents inhibit prostaglandin synthesis and can decrease blood flow to the cochlea, leading to cellular metabolic stress. Patients frequently report tinnitus, which is often reversible once the medication is discontinued. Monitoring is essential as chronic high-dose therapy can result in a more persistent sensorineural hearing impairment. Choice D rationale Vancomycin is a potent glycopeptide antibiotic used for serious gram-positive infections. It is recognized for its potential to cause nephrotoxicity and ototoxicity, especially when serum trough levels exceed the normal range of 15 to 20 mcg/mL. The mechanism involves direct damage to the auditory nerve or the cochlear hair cells. Risk increases significantly when combined with other ototoxic drugs, requiring close monitoring of hearing and renal function. Choice E rationale Cimetidine is a histamine H2-receptor antagonist used to reduce gastric acid secretion in conditions like peptic ulcer disease and GERD. While it has several systemic side effects and drug interactions due to cytochrome P450 inhibition, it is not classified as an ototoxic medication. It does not typically interfere with the delicate neurosensory structures of the ear or the fluid dynamics necessary for normal auditory processing.